BENLYSTA AUTOINJECTOR DOSING

BENLYSTA
AUTOINJECTOR DOSING

 

The BENLYSTA Autoinjector is
approved for subcutaneous (SC) use in
patients
with lupus or lupus nephritis
aged 18 years or older.

Recommended dosing for patients with lupus

Recommended dosing for patients with lupus

Diagram: Recommended subcutaneous dosing for patients with lupus

Recommended dosing for patients with active lupus nephritis

Recommended dosing for patients with active lupus nephritis

Diagram: Recommended subcutaneous dosing for patients with active lupus nephritis
Diagram: Recommended subcutaneous dosing for patients with active lupus nephritis

200 mg/mL single-dose prefilled Autoinjector
For full instructions, refer to the full Prescribing Information for BENLYSTA.

200 mg/mL single-dose prefilled Autoinjector

For full instructions, refer to the full Prescribing Information for BENLYSTA.

* The 400-mg dose requires administration of
2 autoinjectors (2 x 200 mg). The dose is given via subcutaneous injection
in the abdomen or thigh. When the 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.

DID YOU KNOW?

76%

of patients with lupus
taking BENLYSTA preferred
administration with the Autoinjector over intravenous
(IV) infusion.1,2*
(follow-up survey; n=42)

(follow-up survey; n=42)

* A follow-up survey was conducted in patients with
SLE (N=43) who completed open-label, multi-dose, usability, tolerability, and safety study of subcutaneous (SC) belimumab where they were switched from IV or prefilled syringe belimumab to self-administered doses using the autoinjector for 8 weekly doses. Patients (n=42) were asked, “What is your preference for receiving BENLYSTA: using the autoinjector or IV?” 

INSTRUCTIONS FOR USE

Watch the video below to learn how to administer the BENLYSTA Autoinjector.

INSTRUCTIONS FOR USE

Watch the video below to
learn how to administer the
BENLYSTA Autoinjector.

Expand all       Collapse all

  • INSTRUCTIONS FOR USE FOR THE BENLYSTA AUTOINJECTOR

    • It is recommended that the first subcutaneous injection of BENLYSTA should be under the supervision of a healthcare professional. The healthcare provider should provide proper training
      in subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions. A patient may self-inject, or the patient caregiver may administer BENLYSTA subcutaneously after the healthcare provider determines it is appropriate.
    • Instruct the patient or patient caregiver to follow the directions for administration provided
      in the Instructions for Use.
    • Instruct the patient to remove the Autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes prior to the subcutaneous injection. Do not warm BENLYSTA in any other way.
    • Prior to administration, instruct the patient or patient caregiver to visually inspect the window
      of the Autoinjector or the prefilled syringe for particulate matter or discoloration. BENLYSTA
      should be clear to opalescent and colorless to pale yellow. Do not use BENLYSTA if the product exhibits discoloration or particulate matter. Instruct the patient not to use the BENLYSTA Autoinjector or prefilled syringe if dropped on a hard surface.
    • When injecting in the same body region, advise the patient to use a different injection site
      for each injection; never give injections into areas where the skin is tender, bruised, red, or hard. When a 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.
    • Instruct the patient to administer BENLYSTA 200 mg once a week, preferably on the same
      day each week.
    • It is recommended that the first subcutaneous injection of BENLYSTA should be under the supervision of a healthcare professional. The healthcare provider should provide proper training in subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions. A patient may self-inject, or the patient caregiver may administer BENLYSTA subcutaneously after the healthcare provider determines it is appropriate.
    • Instruct the patient or patient caregiver to follow the directions for administration provided in the Instructions for Use.
    • Instruct the patient to remove the Autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes prior to the subcutaneous injection. Do not warm BENLYSTA in any other way.
    • Prior to administration, instruct the patient or patient caregiver to visually inspect the window of the Autoinjector or the prefilled syringe for particulate matter or discoloration. BENLYSTA should be clear to opalescent and colorless to pale yellow. Do not use BENLYSTA if the product exhibits discoloration or particulate matter. Instruct the patient not to use the BENLYSTA Autoinjector or prefilled syringe if dropped on a hard surface.
    • When injecting in the same body region, advise the patient to use a different injection site for each injection; never give injections into areas where the skin is tender, bruised, red, or hard. When a 400-mg dose is administered at the same site, it is recommended that the 2 individual 200-mg injections be administered at least 5 cm (approximately 2 inches) apart.
    • Instruct the patient to administer BENLYSTA 200 mg once a week, preferably on the same day each week.

    If a dose is missed, instruct the patient to administer a dose as soon as the patient remembers. Thereafter, the patient can resume dosing on their usual day of administration or start a new weekly schedule from the day that the missed dose was administered.

    BENLYSTA SC Instructions for Use for Patients (English)

    BENLYSTA SC Instructions for Use for Patients (Spanish)

  • STORAGE AND HANDLING FOR THE BENLYSTA AUTOINJECTOR

    • Store in the refrigerator at 36–46°F (2–8°C)
    • Keep in the original carton until use to protect from light
    • Do not shake or freeze BENLYSTA
    • Avoid exposure to heat
    • Do not use or place back in the refrigerator if left at room temperature for more than 12 hours
    • Safely throw away medicine that is out of date or no longer prescribed
    • Keep out of reach of children

99%

of patients with lupus successfully administered
BENLYSTA via Autoinjector.3*
(open-label study; n=90)

* Open-label study assessed the correct use of the BENLYSTA Autoinjector in adult SLE patients (N=95). BENLYSTA was administered as a 200-mg subcutaneous injection by the patient for 8 weekly doses after being trained on proper use with the Autoinjector at Screening and Day 0. Successful use was determined by investigator observation and/or their review of the patient diary based on the Instructions for Use. Primary endpoint was to evaluate successful administration of observed first and second doses (Weeks 1 & 2; n/N=89/90).3

BENLYSTA IV IS AVAILABLE FOR PATIENTS
WHO PREFER IN-OFFICE ADMINISTRATION

BENLYSTA IV IS AVAILABLE FOR PATIENTS WHO PREFER IN-OFFICE ADMINISTRATION

Recommended dosing for patients with lupus and lupus nephritis 

Recommended dosing for patients with lupus and lupus nephritis 

BENLYSTA IV is for intravenous infusion only in patients with lupus 5 years and older and patients with lupus nephritis aged 18 years and older.

BENLYSTA IV is administered as a 1-hour infusion

BENLYSTA IV is administered as a 1-hour infusion

10 mg/kg administered every 2 weeks for the first 3 doses and every 4 weeks thereafter.

Diagram: Recommended IV dosing for patients with lupus and lupus nephritis
Diagram: Recommended IV dosing for patients with lupus and lupus nephritis

Scheduling first 3 doses in advance may be helpful for patients

Scheduling first 3 doses in advance may be helpful for patients

BENLYSTA IV is supplied as:

  • 120 mg in a 5-mL single-dose vial
  • 400 mg in a 20-mL single-dose vial

For full instructions, refer to the full Prescribing Information for BENLYSTA.

  • Instructions for use for BENLYSTA IV

    • BENLYSTA IV is supplied as a sterile, preservative-free, lyophilized powder for IV infusion only.
      • Reconstitute and dilute using aseptic technique prior to administration.
    • Diluted solution should be administered over 1 hour.
      • Do not administer as an IV push or bolus.
      • Total time from reconstitution to completion should not exceed
        8 hours.
    • Prophylactic premedication may be used to manage the risk of infusion and hypersensitivity reactions.
      • IV should be administered by a healthcare provider prepared to manage anaphylaxis.
    • Slow or interrupt infusion rate if infusion reaction occurs.
    • Discontinue immediately if the patient experiences a serious hypersensitivity reaction.
    • BENLYSTA IV should not be infused concomitantly in the same IV line with other agents.
  • Storage and Handling for BENLYSTA IV

    • Refrigerate vials at 36–46°F (2–8°C)
    • Store vials in the original carton until use to protect from light
    • Do not freeze
    • Avoid exposure to heat

USEFUL TOOLS

Find the vial combination
that helps minimize product waste

VIAL CALCULATOR 

Icon: IV bag

Calculate patients’
infusion dates

 

INFUSION SCHEDULER

Icon: Calendar

Give your patients the option
of at-home convenience –
Choose BENLYSTA today

Give your patients the option of at-home convenience – Choose BENLYSTA today

BENLYSTA Patient
BENLYSTA Patient